BN vs CNS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BN and CNS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BN and CNS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Brookfield Corporation sits at the top of the Brookfield group and reports through three pillars. Asset management runs through its roughly 73% interest in Brookfield Asset Management, whose fee-bearing capital reached ~$614 billion in the first quarter of 2026, up ~12% year over year on ~$67 billion of year-to-date fundraising that included a ~$40 billion investment mandate from UK annuity provider Just Group. Wealth solutions is the annuity and pension-risk-transfer business (Brookfield Wealth Solutions, built from American National, Argo Group and American Equity Life) that gathers policyholder money and invests it alongside Brookfield's own funds. The third pillar is the operating businesses, held partly through the listed affiliates: Brookfield Renewable (BEP/BEPC), Brookfield Infrastructure (BIP/BIPC), Brookfield Business Partners (BBU/BBUC) and a wholly owned real estate book that includes Canary Wharf, Brookfield Place and Ala Moana Center. Bruce Flatt has run the company since 2002, and the December 2022 reorganisation is what created the BN-versus-BAM split: BN kept the balance sheet and the carried interest, BAM was carved out as the pure-play, high-payout manager.

Full BN guide

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).

Full CNS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BN drivers: Fee-bearing capital and carried interest at BAM; The insurance and annuity flywheel.
• CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The reported financials are hard to underwrite: consolidation pulls in revenue and debt from entities BN does not fully own, so ~$79 billion of trailing revenue and ~$1.2 billion of attributable net income describe the same company, and an investor has to accept management's distributable earnings framing to value it. For CNS, cNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings.

Pick BN if you believe its drivers more; CNS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BN and CNS guides.

BN. First quarter 2026 revenue was ~$18.6 billion with net income of ~$1.04 billion, against ~$215 million a year earlier, so the year-over-year jump reflects mark movements more than a step change in operations. The reported P/E near ~86x is not a like-for-like multiple: depreciation on infrastructure and the share of consolidated profit belonging to outside partners both sit between revenue and attributable earnings. Second quarter 2026 results are scheduled for August 13, 2026, with consensus around ~$0.65 per share before the release.

CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.

Headline figures (approximate, August 2026): BN shows share price / market cap ~$44 per share, ~$101 billion (Aug 7, 2026 close), revenue (ttm) ~$79 billion, net income attributable (ttm) ~$1.2 billion, a reported P/E near ~86x, distributable earnings (q1 2026) ~$1.6 billion, ~$0.66 per share (~$1.4 billion before realizations); CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82.

BN and CNS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BN and CNS exposure against your real portfolio. It is not an investment adviser.